RELMADA THERAPEUTICS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

RELMADA THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $3.50 million for the year ending 2025.

  • RELMADA THERAPEUTICS, INC. showed a decrease of -9.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from RELMADA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2013: $1.56 million | Q3 2013: $3.95 million | Q1 2014: $2.46 million | Q2 2014: $25.56 million | Q3 2014: $27.39 million | Q4 2014: $31.42 million | Q1 2015: $26.96 million | Q2 2015: $22.47 million | Q3 2015: $19.17 million | Q4 2015: $15.13 million | Q1 2016: $11.35 million | Q3 2016: $6.22 million | Q4 2016: $4.71 million | Q1 2017: $2.76 million | Q3 2017: $4.68 million | Q4 2017: $5.94 million | Q1 2018: $4.26 million | Q3 2018: $887.5 thousand | Q1 2019: $2.05 million | Q3 2019: $7.85 million | Q4 2019: $36.28 million | Q1 2020: $12.23 million | Q2 2020: $13.82 million | Q3 2020: $7.54 million | Q4 2020: $2.50 million | Q1 2021: $3.80 million | Q2 2021: $4.67 million | Q3 2021: $11.45 million | Q1 2023: $28.89 million | Q2 2023: $14.47 million | Q3 2023: $6.70 million | Q1 2024: $1.34 million | Q2 2024: $2.09 million | Q3 2024: $1.48 million | Q1 2025: $1.15 million | Q2 2025: $1.35 million | Q3 2025: $1.38 million.
  • Over the full 16 years of available data (2012 to 2025), RELMADA THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 97.2%.
  • Historical annual values: Fiscal year 2025: $3.50 million | Fiscal year 2024: $3.86 million | Fiscal year 2023: $4.09 million | Fiscal year 2022: $5.40 million | Fiscal year 2021: $44.44 million | Fiscal year 2020: $2.50 million | Fiscal year 2019: $36.28 million | Fiscal year 2019: $9.22 million | Fiscal year 2018: $2.43 million | Fiscal year 2018: $2.24 million | Fiscal year 2017: $1.71 million | Fiscal year 2016: $8.50 million | Fiscal year 2015: $22.47 million | Fiscal year 2014: $25.56 million | Fiscal year 2013: $3.52 million | Fiscal year 2012: $1.77 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: